NCT01307969

Brief Summary

This blinded cross-over study aim to evaluate the efficacy of liposome-encapsulated ropivacaine formulation for dental anesthesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Feb 2007

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2007

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2007

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2007

Completed
3.7 years until next milestone

First Submitted

Initial submission to the registry

February 16, 2011

Completed
15 days until next milestone

First Posted

Study publicly available on registry

March 3, 2011

Completed
Last Updated

March 3, 2011

Status Verified

February 1, 2011

Enrollment Period

3 months

First QC Date

February 16, 2011

Last Update Submit

March 2, 2011

Conditions

Keywords

liposomesropivacainedental anesthesiadentistry

Outcome Measures

Primary Outcomes (1)

  • After anesthetic injection the pulpal response was assessed by an electrical pulp tester.

    100 minutes

Secondary Outcomes (1)

  • Duration of soft tissue anesthesia was measured as the time from beginning to end of lip and gingival numbness.

    240 minutes

Study Arms (1)

Anesthetic efficacy

EXPERIMENTAL

Local anesthetics were injected at the apex of the maxillary right canine.

Drug: Ropivacaine

Interventions

1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.

Also known as: 0,5% ropivacaine encapsulated in liposomes, 0,5% ropivacaine with epinephrine 1:200.000, 2% lidocaine with epinephrine 1:100.000
Anesthetic efficacy

Eligibility Criteria

Age18 Years - 44 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy

You may not qualify if:

  • Volunteers were free from cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal and haematological diseases, psychiatric disorders and allergy to local anesthetics

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Piracicaba Dental School

Piracicaba, São Paulo, Brazil

Location

Related Publications (1)

  • Franz-Montan M, de Paula E, Groppo FC, Ranali J, Volpato MC. Efficacy of liposome-encapsulated 0.5% ropivacaine in maxillary dental anaesthesia. Br J Oral Maxillofac Surg. 2012 Jul;50(5):454-8. doi: 10.1016/j.bjoms.2011.07.010. Epub 2011 Aug 9.

MeSH Terms

Interventions

RopivacaineLiposomesEpinephrineLidocaine

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesMembranes, ArtificialBiomedical and Dental MaterialsDrug CarriersDosage FormsPharmaceutical PreparationsManufactured MaterialsTechnology, Industry, and AgricultureBiomimetic MaterialsEthanolaminesAmino AlcoholsAlcoholsBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsAcetanilides

Study Officials

  • Michelle Franz-Montan, PhD

    Researcher at Unicamp

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 16, 2011

First Posted

March 3, 2011

Study Start

February 1, 2007

Primary Completion

May 1, 2007

Study Completion

June 1, 2007

Last Updated

March 3, 2011

Record last verified: 2011-02

Locations